Haberler: Kovid-19

Kovid-19

İçinde

("Covid 19","Kovid 19","Koronavirüs","Korona virüs","Biontech","Sinovac","Delta ","Lambda ","Covid19","Kovid19","Covid-19","Kovid-19","Omicron ","Omikron ")

kelimelerinden biri ile,

(" aşı","vaccine","varyant","variant","pandemi","vaka "," dalga","pandemic","salgın")

kelimelerinden birinin aynı anda geçtiği haberler

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021 As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422857

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021 In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422060

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021 The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422061

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021 On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421658

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021 Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421542

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021 Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421539

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021 In U.S. hospitals during January-March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421438

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021 This report describes an investigation in Maryland of two linked clusters of COVID-19 cases identified as the B.1.351 variant. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421458

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021 The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416

Pazar, 23 Ocak 2022, 12:09 ÖÖ	Haber Kaynağı: Çeşitli Haber Siteleri Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021 Twenty-two possible breakthrough SARS-CoV-2 infections occurred among fully vaccinated persons ≥14 days after their second dose of COVID-19 vaccine. Two thirds of persons were asymptomatic. A minority of persons with breakthrough infection experienced mild to moderate COVID-19-like symptoms; two COVID-19-related hospitalizations and one death occurred. No facility-associated secondary transmission was identified. https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420772